Elicio TherapeuticsELTX
13F holders, Q3 2024 (September 30)18holders −2
3new positions
4sold out
1famous investor
$5.04avg. 13F price*
At the end of Q3 2024, 18 institutions reported holding Elicio Therapeutics Inc. (ELTX) in their 13F filings, down 2 from Q2 2024. 3 opened new positions and 4 sold out. The largest holders were Vanguard Group Inc. ($1.2M), Geode Capital Management, LLC ($360K) and CM Management, LLC ($252K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Elicio Therapeutics Inc.
- CUSIP
- 28657F103
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $70K |
| Exits | 4 | $660K |
All 13F filers, Q2 2024 → Q3 2024: 53,319 shares bought and 161,299 shares sold, net −107,980 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 18 holders
| Vanguard Group Inc. | 0.00% | Add +8.4% | 245,262 | $1.2M |
| Geode Capital Management, LLC | 0.00% | Add +0.1% | 71,574 | $360K |
| CM Management, LLC | 0.20% | No change | 50,000 | $252K |
| Northern Trust Corp. | 0.00% | Add +175.2% | 30,769 | $155K |
| State Street Corp. | 0.00% | No change | 21,900 | $110K |
| BlackRock, Inc. | 0.00% | — | 19,693 | $99K |
| Meyer Handelman Co. | 0.00% | No change | 13,899 | $70K |
| Citadel Advisors | 0.00% | New | 12,856 | $65K |
| Bridgeway Capital Management, LLC | 0.00% | No change | 12,500 | $63K |
| CIBC Private Wealth Group LLC | 0.00% | No change | 7,000 | $43K |
| Steward Partners Investment Advisory, LLC | 0.00% | No change | 1,554 | $8K |
| Bank of America Corp. | 0.00% | Add +2.8% | 1,236 | $6K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 950 | $5K |
| UBS Group AG | 0.00% | Add +4888.2% | 848 | $4K |
| National Bank of Canada | 0.00% | Reduce -46.7% | 800 | $4K |
| Citigroup Inc. | 0.00% | No change | 374 | $2K |
| Morgan Stanley | 0.00% | Add +4.3% | 240 | $1K |
| JPMorgan Chase & Co. | 0.00% | New | 18 | $91 |
"% of holder's portfolio" is ELTX's weight in each manager's 13F, not the share of Elicio Therapeutics Inc. the manager owns.